Johnson & Johnson (NYSE:JNJ) issued an update on its FY18 earnings guidance on Tuesday morning. The company provided EPS guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.87. The company issued revenue guidance of $80.6-81.4 billion, compared to the consensus revenue estimate of $80.71 billion.
Johnson & Johnson (NYSE:JNJ) traded down $0.29 during midday trading on Wednesday, reaching $129.67. The company’s stock had a trading volume of 6,260,000 shares, compared to its average volume of 9,410,000. Johnson & Johnson has a 1-year low of $115.32 and a 1-year high of $148.32. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The stock has a market cap of $348,360.00, a PE ratio of 332.49, a P/E/G ratio of 2.34 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.02. The business had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The business’s revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the business posted $1.58 EPS. equities analysts forecast that Johnson & Johnson will post 8.08 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s payout ratio is presently 861.54%.
JNJ has been the subject of a number of research analyst reports. Vetr upgraded Johnson & Johnson from a hold rating to a buy rating and set a $152.28 target price for the company in a research note on Tuesday, January 23rd. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the company an outperform rating in a research note on Thursday, October 19th. Royal Bank of Canada raised their target price on Johnson & Johnson from $144.00 to $147.00 and gave the company an outperform rating in a research note on Wednesday, October 18th. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a hold rating in a research note on Wednesday, January 24th. Finally, Citigroup lifted their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the company a buy rating in a research note on Monday, October 23rd. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Hold and an average target price of $146.16.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Harding Loevner LP purchased a new position in shares of Johnson & Johnson in the second quarter valued at about $106,000. IHT Wealth Management LLC lifted its position in shares of Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares in the last quarter. Mountain Capital Investment Advisors Inc purchased a new position in shares of Johnson & Johnson in the second quarter valued at about $124,000. Financial Gravity Companies Inc. purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at about $143,000. Finally, Delpha Capital Management LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at about $166,000. Institutional investors own 65.53% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/14/johnson-johnson-jnj-issues-fy18-earnings-guidance-3.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.